Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Trial Details

NCT ID

NCT07755436

Phase

PHASE1

Sponsor

ArriVent BioPharma, Inc.

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

• ARR-002

Locations (sample)

• Orlando, Florida, United States|28.53834,-81.37924
• Boston, Massachusetts, United States|42.35843,-71.05977
• Nashville, Tennessee, United States|36.16589,-86.78444
• Houston, Texas, United States|29.76328,-95.36327
• Irving, Texas, United States|32.81402,-96.94889

Key Eligibility Criteria

• Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum…
• Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
• Tumor specimen available for testing, or agree to biopsy at baseline.
• The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.